Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Immortals vs PrescribedRX

Immortals
Graded #284

Higher grade

vs+2.799999999999997
PrescribedRX
Graded #351

Lower grade

The verdict

Immortals takes it — 61.8/100 to 59/100.

Immortals grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Immortals is a LegitScript-certified longevity telehealth platform founded by Bryan Johnson, offering compounded semaglutide (Semaglutide/Glycine/B12) and tirzepatide (Tirzepatide/Glycine/B12) as microdose…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueImmortals +7
54
47
Dose & formulationPrescribedRX +13
64
77
Clinical oversightImmortals +14
88
74
Labs & monitoringImmortals +2
54
52
FulfillmentImmortals +4
68
64
Contract termsEven
20
20
Immortals · left barPrescribedRX · right bar

The numbers

MetricImmortalsPrescribedRX
WeighScore61.8/10059/100
GradeCC
Scorecard rank#284#351
Semaglutide$167/mo (microdose tier, compounded)$189/mo (compounded)
Tirzepatide$180/mo (microdose tier, compounded)$276/mo (compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Immortals

Graded #284 · C

Strengths

  • LegitScript certified (ID 50458743) with board-certified U.S. physician review within 72 hours
  • Physician consult + prescription bundled in price — 'You pay for treatment. That's it' with no added fees
  • Competitive pricing: semaglutide microdose from $167/month, tirzepatide from $180/month (promotional)
  • Unlimited provider messaging for 12 months included; video consults available
  • Founded by Bryan Johnson and Kate Tolo; clinical lead Dr. Carl Seger, M.D. (preventive/longevity medicine)

Where it loses points

  • Microdose framing uses sub-clinical doses — lower weight-loss efficacy than standard GLP-1 protocols
  • Quarterly commitment only — 3-month minimum, paid upfront ($501–$540/quarter); no monthly flexibility
  • State availability not publicly listed; 'eligible U.S. states' with no specific state list
  • Labs not included; baseline bloodwork protocol not disclosed on any public page
  • Compounding pharmacy not named; no 503A/503B accreditation details disclosed
PrescribedRX

Graded #351 · C

Strengths

  • Compounded semaglutide ($189/mo) and tirzepatide ($276/mo) injectables, with lower per-month pricing on the 3-month plans ($176 and $233/mo)
  • Clear, upfront plan pages showing monthly and multi-month pricing with no surprise fees
  • Care from licensed US providers with monthly home delivery and ongoing dose support
  • Bilingual English/Spanish site and a broader telehealth menu (TRT, longevity, hair, sexual health) for people who want more than weight loss

Where it loses points

  • Doesn't publish the states it serves — you only learn eligibility after starting the intake
  • Compounding pharmacies aren't named on the site
  • Mid-range pricing — cheaper compounded GLP-1 options exist and the 3-month discount is modest
  • Compounded semaglutide and tirzepatide injectables only — no brand-name or oral options
  • Self-hosted affiliate program (not a vetted network); Florida/Palm Beach framing suggests a regional lean

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard